XYLT1

Across TCGA pan-cancer cohorts, XYLT1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of XYLT1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where XYLT1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types XYLT1 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

LUAD, PDAC, and HNSC are the cancer types where XYLT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in XYLT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−1.100	<.001	8	view →
PDAC	Female	All	+0.563	<.001	8	view →
HNSC	Male	All	−0.242	.008	6	view →
OV	All	All	−1.531	.001	2	view →
LSCC	Female	All	+0.328	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

XYLT1–LUAD

Open the LUAD breakdown →